Data on interaction between adeno-associated virus and U87 cell via cRGD chemical modification
Chuanling Zhang,
Tianzhuo Yao,
Yongxiang Zheng,
Zhongjun Li,
Lihe Zhang,
Demin Zhou
Affiliations
Chuanling Zhang
State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, No. 38, Xueyuan Road, Beijing 100191, China
Tianzhuo Yao
State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, No. 38, Xueyuan Road, Beijing 100191, China
Yongxiang Zheng
State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, No. 38, Xueyuan Road, Beijing 100191, China
Zhongjun Li
State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, No. 38, Xueyuan Road, Beijing 100191, China
Lihe Zhang
State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, No. 38, Xueyuan Road, Beijing 100191, China
Demin Zhou
Corresponding author. Tel.: +86 10 8280 5857; fax: +86 10 8280 5519.; State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, No. 38, Xueyuan Road, Beijing 100191, China
RGD tripeptide is a specific, high-affinity ligand for integrin, which is highly expressed in cancer cells. We previously reported that cRGD chemically modified AAV2 (AAV2N587+1/azido+RGD) showed significantly enhanced infectivity compared to RGD genetically inserted AAV2 (AAV2N587+RGD) (10.1016/j.biomaterials.2015.11.066) [1]. Herein we provide the binding ability analysis of RGD modified AAV2 and U87 cell by flow cytometry and the theoretical working model of RGD–αvβ3 integrin interaction. Keywords: Adeno-associated virus, Viral modification, Targeted gene delivery
